Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prevention of Bacterial Infections in the Newborn by Pre-delivery Administration of Azithromycin (AZI): a Placebo-controlled Randomized Trial

Next Previous
Trial Profile

Prevention of Bacterial Infections in the Newborn by Pre-delivery Administration of Azithromycin (AZI): a Placebo-controlled Randomized Trial

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 May 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azithromycin (Primary)
  • Indications Bacterial infections; Gram-positive infections; Neonatal infections
  • Focus Therapeutic Use
  • Acronyms PregnAnZI

Most Recent Events

  • 23 May 2020 Results of post hoc analysis, evaluating the effect of intra-partum AZI on the prevalence of the macrolide resistance genes (msr(A) and ermC) in the nasopharynx at different time points during infancy, published in the Clinical Infectious Diseases
  • 19 Aug 2019 Results describing bacterial population dynamics and resistance mechanism published in the Journal of Antimicrobial Chemotherapy
  • 28 Mar 2018 Results (n=461) assessing long-term impact of oral azithromycin taken by gambian women during labour on prevalence and antibiotic susceptibility of s. pneumoniae and s. aureus in their infants: follow up of a randomized clinical trial were published in the Clinical Infectious Diseases.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top